A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy Clinical Trial

Official title:

A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05174416
• Other study ID #: LB2001-301
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: January 4, 2022
• Est. completion date: August 2024

Study information

• Verified date: March 2024
• Source: LianBio LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.

Description:

This is a randomized, double-blinded, placebo-controlled clinical study witha long-term extension to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM. Approximately 81eligible participants will be enrolled and randomized in a 2:1 ratio (mavacamten:placebo). Participants will receive mavacamten or matching placebofor 30 weeks indouble-blinded manner. After 30-week double-blinded placebo-controlled treatment, eligible participants will receive mavacamten for additional 48 weeks (placebogroup: switch from placebo to mavacamten, mavacamten group: maintain on mavacamten).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 81
• Est. completion date: August 2024
• Est. primary completion date: March 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Is at least 18 years old at screening.

• Body weight is greater than 45 kg at screening.

• Has adequate acoustic windows to enable accurate TTEs

• Diagnosed with oHCM

• Has documented LVEF = 55% at rest.

• Has a valid measurement of Valsalva LVOT peak gradient at screening

• Has NYHA Class II or III symptoms at screening

• Female participants must not be pregnant or lactating

• Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to national, local, and institutional guidelines before the first study specific procedure.

Exclusion Criteria:

• Participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to screening, or at least 5 times the respective elimination half-life (if known), whichever is longer.

• Causing cardiac hypertrophy in other reasons

• Previously participated in a clinical study with mavacamten.

• Hypersensitivity to any of the components of the mavacamten formulation.

• Current treatment (within 14 days prior to screening) or planned treatment during the double-blinded treatment with a combination of beta-blockers and verapamil or a combination of beta-blockers and diltiazem.

• Has been successfully treated with invasive septal reduction

• Has documented obstructive coronary artery disease

• Has known moderate or severe (as per investigator's judgment) aortic valve stenosis, constrictive pericarditis, or clinically significant congenital heart disease at screening.

• Has any acute or serious comorbid condition that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.

• History of malignant disease within 10 years of screening

• Has safety laboratory parameters outside normal limits at screening as assessed by the local laboratory

• Has a positive serologic test at screening for infection with human immunodeficiency virus, hepatitis C virus, or hepatitis B virus surface antigen.

• Known uncured COVID-19 (coronavirus disease 2019) infection or with severe complication before screening.

• Has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

• Prior treatment with cardio toxic agents.

• Unable to comply with the study requirements, including the number of required visits to the clinical site.

• Is a first degree relative of personnel directly affiliated with the study at the clinical study site, any study vendor, or the study sponsor.

• Identified as alcohol addicts.

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Hypertrophy
• Obstructive Hypertrophic Cardiomyopathy

Intervention

Drug:
• Mavacamten
Mavacamten Capsules
• Placebo
Matching PBO capsules during placebo controlled period,and mavacamten capsules during long term extension period

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
LianBio LLC

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline to Week 30 in Valsalva left ventricular outflow tract (LVOT) peak gradient	To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography	30 weeks
Secondary	Change from baseline to Week 30 in resting LVOT peak gradient	To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.	30 weeks
Secondary	Proportion of participants achieving a Valsalva LVOT peak gradient < 30 mmHg at Week 30	To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.	30 weeks
Secondary	Proportion of participants achieving a Valsalva LVOT peak gradient < 50 mmHg at Week 30.	To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.	30 weeks
Secondary	Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) functional classification from baseline to Week 30	To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms	30 weeks
Secondary	Change from baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)	To compare the effect of a 30-week course of mavacamten with placebo on Participant-Reported health status individually	30 weeks
Secondary	Change from baseline to Week 30 in N-terminal pro-B-type natriuretic peptide (NT-proBNP)	To compare the effect of a 30-week course of mavacamten on cardiac biomarkers	30 weeks
Secondary	Change from baseline to Week 30 in cardiac troponin	To compare the effect of a 30-week course of mavacamten on cardiac biomarkers	30 weeks
Secondary	Change from baseline to Week 30 in left ventricular (LV) mass index	To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging.	30 weeks